Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Significant and symptomatic cardiac comorbidity is a contraindication to adjuvant trastuzumab in breast cancer patients. However, some patients with asymptomatic, nonlimiting cardiac comorbidity and normal baseline left ventricular ejection fraction (LVEF) receive adjuvant trastuzumab in the clinical practice. We sought to describe the tolerability of trastuzumab in these patients.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Breast J

Title: The breast journal

Publisher: Wiley

ISSN (Electronic): 1524-4741

ISSN (Print): 1075-122X

Publication date (Electronic): May 2019

Volume: 25

Issue: 3

Affiliations

[1 ] Medical Oncology, Cardinal Massaia Hospital, Asti, Italy.

[2 ] Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.

[3 ] Medical Oncology B, Regina Elena National Cancer Institute, Rome, Italy.

[4 ] Medical Oncology 2, AOU Citta' della Salute e della Scienza, Turin, Italy.

[5 ] Medical Oncology, IRCCS AOU San Martino - IST, Genova, Italy.

[6 ] Medical Oncology, S. Croce e Carle Teaching Hospital, Cuneo, Italy.

[7 ] Medical Oncology, S. Lorenzo Hospital, Carmagnola, Turin, Italy.

[8 ] Cardiology, Candiolo Cancer Institute, FPO- IRCCS, Turin, Italy.

Article

DOI: 10.1111/tbj.13240

PubMed ID: 30932296

SO-VID: 18198269-b2f6-45cc-9ac5-e71ad917a9dd

History

Keywords: cardiotoxicity,trastuzumab,cardiac comorbidity,breast cancer

Data availability:

Keywords: cardiotoxicity, trastuzumab, cardiac comorbidity, breast cancer

Comments

Comment on this article

Cited by 2

See all cited by